Ventyx Biosciences Inc (VTYX)
4.74
-0.24
(-4.82%)
USD |
NASDAQ |
May 17, 16:00
4.74
0.00 (0.00%)
After-Hours: 20:00
Ventyx Biosciences Enterprise Value: 30.88M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 30.88M |
| May 16, 2024 | 48.50M |
| May 15, 2024 | -7.190M |
| May 14, 2024 | -8.600M |
| May 13, 2024 | -12.12M |
| May 10, 2024 | -14.24M |
| May 09, 2024 | 13.25M |
| May 08, 2024 | 10.43M |
| May 07, 2024 | 22.07M |
| May 06, 2024 | 29.47M |
| May 03, 2024 | 39.34M |
| May 02, 2024 | 43.57M |
| May 01, 2024 | 27.35M |
| April 30, 2024 | -38.92M |
| April 29, 2024 | -32.22M |
| April 26, 2024 | -25.52M |
| April 25, 2024 | -16.36M |
| April 24, 2024 | -3.665M |
| April 23, 2024 | 4.090M |
| April 22, 2024 | 0.5646M |
| April 19, 2024 | 12.55M |
| April 18, 2024 | 4.090M |
| April 17, 2024 | 6.204M |
| April 16, 2024 | 32.99M |
| April 15, 2024 | 26.65M |
| Date | Value |
|---|---|
| April 12, 2024 | 21.71M |
| April 11, 2024 | 21.71M |
| April 10, 2024 | 32.29M |
| April 09, 2024 | 52.73M |
| April 08, 2024 | 30.17M |
| April 05, 2024 | 38.63M |
| April 04, 2024 | 42.86M |
| April 03, 2024 | 62.60M |
| April 02, 2024 | 66.81M |
| April 01, 2024 | 91.48M |
| March 28, 2024 | 135.12M |
| March 27, 2024 | 156.60M |
| March 26, 2024 | 160.48M |
| March 25, 2024 | 208.37M |
| March 22, 2024 | 219.64M |
| March 21, 2024 | 265.41M |
| March 20, 2024 | 275.98M |
| March 19, 2024 | 304.15M |
| March 18, 2024 | 309.78M |
| March 15, 2024 | 290.06M |
| March 14, 2024 | 293.58M |
| March 13, 2024 | 340.07M |
| March 12, 2024 | 246.57M |
| March 11, 2024 | 224.06M |
| March 08, 2024 | 335.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-178.00M
Minimum
Dec 20 2023
2.340B
Maximum
Mar 03 2023
897.80M
Average
787.21M
Median
Oct 13 2023
Enterprise Value Benchmarks
| Anavex Life Sciences Corp | 245.73M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | 15.11M |
| Checkpoint Therapeutics Inc | 58.04M |
| RAPT Therapeutics Inc | -0.5689M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.57M |
| Total Expenses (Quarterly) | 41.77M |
| EPS Diluted (Quarterly) | -0.62 |
| Earnings Yield | -68.50% |